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1726-4Detection of chromosome abnormalities: Beyond conventional
karyotypingPregnancy loss is a gravely unhappy and emotionally
stressful event for any couple. Besides having to address what
may be a couple's psychosocial embarrassment due to their
loss, one of the challenges for most researchers is how to
identify these pregnancy loss cases with genetic defects that
are destined to miscarry from other treatable cases.1 It remains
indisputable that chromosomal karyotyping is the gold
standard for prenatal diagnosis, including pregnancy loss.2
However, researchers can obtain virtually the same or better
diagnostic information for detecting gains and losses of
genetic material across the genome using microarray analysis,
also known as molecular karyotyping and/or chromosomal
array analysis, including array-based comparative genomic
hybridization3 and single nucleotide polymorphism (SNP)
array.2 All of these different arrays create an entire genome
scanning panel. Comparative genomic hybridization is able to
discover and map genomic regions for chromosomal gains or
losses in a single experiment without knowledge pertaining to
the locations of regions of abnormalities.3 SNP combing
across the genome (approximately 1/10 kb) with an infor-
matics technique is used to detect gains and losses and iden-
tifies maternal cell contamination, triploidy, and uniparental
disomy.4
In this issue, Lin et al5 have authored an interesting article
entitled Improved assay performance of single nucleotide
polymorphism array over conventional karyotyping in ana-
lyzing products of conception. We heartily applaud the pub-
lication of this article, because the diagnoses were consistent
with previous reports based on traditional cell culture and
karyotyping of products of conception. In Lin et al's5 study,
approximately 64.5% (100/155) of samples were cytogeneti-
cally abnormal (including 52% single trisomy, 11% monos-
omy X, and 6% triploidy). SNP array not only demonstrated a
higher success rate for detecting chromosomal abnormalities
(98.1% vs. 85.8%), but also provided an additional ability to
detect pathologic copy number variations and whole-genome
uniparental disomy (UPD) compared with conventional kar-
yotyping (G-banded karyotyping), thus contributing to a
higher detection rate of abnormalities (62.6% vs. 61.3%).5
Furthermore, the use of SNPs also significantly improved
sensitivity to mosaicism.5 By contrast, two cases of chromo-
some translocation and one case of tetraploidy were notx.doi.org/10.1016/j.jcma.2015.04.008
901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Assdetected by SNP but by conventional karyotyping.5 The
authors suggested that SNPs would be an alternative method to
karyotyping in clinical genetic practice. In fact, Pergament
et al6 recently published a very intriguing report, when they
studied 1064 maternal blood samples from 7 weeks of ges-
tation and beyond using the Next-generation Aneuploidy Test
Using SNPs algorithm. This study showed that the test pro-
vided results associated with a high level of sensitivity and
specificity. Furthermore, Levy et al7 reported the full cohort of
identifiable anomalies, regardless of known clinical sig-
nificance, in a large-scale cohort of postmiscarriage products-
of-conception samples analyzed using a high-resolution SNP-
based microarray platform. They concluded that using SNPs
extends the scope of detectable genomic abnormalities and
facilitates reporting true fetal results, supporting the use of
SNP chromosomal microarray analysis for cytogenomic
evaluation of miscarriage specimens when clinically indicated.
Although Lin et al's5 report confirmed the validity of SNP
microarray analysis, the obvious question is: when should
these tests be ordered? Currently, cytogenetic evaluation of
products of conception is not routinely recommended.4 It may
be that the advent of this new technology could compel us to
rethink that policy and start testing this tissue more liberally.
Approximately 25% of all recognized pregnancies ended in
spontaneous miscarriage, with the majority caused by spora-
dic aneuploidy.4 Most authorities do not believe that kar-
yotyping products of conception after one miscarriage will be
beneficial for these parents, because the result would not
change treatment for the vast majority of couples and these
evaluations are too expensive.4 Although cytogenetic inves-
tigation is suggested for those parents with recurrent preg-
nancy loss, this recommendation applies to obtaining parental
karyotypes and not the karyotype of products of conception.8
Additionally, confirming a genetic abnormality in products of
conception, resulting in a lack of further parental evaluation,
could lead to failure to identify another remediable cause for
miscarriage.4 Finally, testing all products of conception might
be considered for purposes of reassuring the parents. How-
ever, the basic cost of the test, coupled with the fact that 50%
of the results would be euploid and could not provide an
explanation for the pregnancy loss, argue against such a
practice.4ociation. All rights reserved.
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that 10.3% of miscarriages occurred in the second trimester,
which requires further discussion. Testing fetal tissue after the
second or third trimester pregnancy loss might obviate the
need to do additional studies, such as imaging for uterine
anomalies9 or testing for antiphospholipid antibody
syndrome.10
Wilson et al11 at the 18th International Society for Prenatal
Diagnosis International Conference on Prenatal Diagnosis and
Therapy, which was held in Brisbane, Australia on July 22,
2014, provided the final consensus summary. Namely, that
while the present genomic diagnostic technology with access
to prenatal testing following an informed consent process
recommendation would probably become a future standard of
care for prenatal screening/diagnosis/therapy, when specific
fetal abnormalities/syndrome are identified, the debate rec-
ommendation could not be completely supported at this time
by the international audience attending the 2014 18th Inter-
national Society for Prenatal Diagnosis meeting in Brisbane,
Australia. In summary, SNP-based microarray analysis of
products of conception is likely to give accurate results for the
majority of parents, however, whether and when it is appro-
priate to perform this analysis remains uncertain.
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